中国药理学通报2017，Vol.33Issue(5)：617-621,5.DOI:10.3969/j.issn.1001-1978.2017.05.006
VEGF融合蛋白疫苗联合环磷酰胺抗小鼠H22肝癌实验研究
Improved antitumor efficacy by combinationtreatment with recombined VEGF protein vaccineand cyclophosphamide in H22 hepatocellular carcinoma bearing-mice
摘要
Abstract
Aim To investigate the antitumor and antiangiogenic effects of combined low-dose cyclophosphamide(CTX)and recombined VEGF protein vaccine.Methods In this experiment,H22 hepatocellular carcinoma model was established in BALB/c mice.Mice were randomly divided into four groups: control group,CTX group(CTX),VEGF protein vaccine group(V2)and CTX plus V2 group(CTX+V2).The anti-tumor efficacy and antiangiogenic effect were investigated using a subcutaneous tumor model and an intradermal tumor model.Western blot and ELISAwere further adopted to detect the specific anti-VEGF antibody.Results CTX+V2 group displayed a lower tumor volume and tumor weight than either the single therapy group in the subcutaneous tumor model(P<005 vs V2,P<001 vs CTX).Meanwhile,CTX+V2 was more effective for antagonizing tumor-associated angiogenesis compared with either the single therapy(P<005 vs V2,P<001 vs CTX).After CTX+V2 immunization,high titer of anti-VEGF antibody was detected by ELISA and verified by Western blot.Conclusion The therapy of CTX combined with V2 has significant synergistic effect against H22 hepatocellular carcinoma.关键词
血管内皮生长因子/抗血管生成/环磷酰胺/蛋白疫苗/H22肝癌/肿瘤联合治疗Key words
vascular endothelial growth factor/anti-angiogenesis/cyclophosphamide/protein vaccine/H22 hepatocellular carcinoma/cancer combined therapy分类
医药卫生引用本文复制引用
司春枫,鲁美钰,王巧云,仲维兰,周玲,杨小平,徐茂磊..VEGF融合蛋白疫苗联合环磷酰胺抗小鼠H22肝癌实验研究[J].中国药理学通报,2017,33(5):617-621,5.基金项目
国家自然科学基金资助项目(No81541158) （No81541158）
山东省优秀中青年科学家科研奖励基金(NoBS2014YY051) （NoBS2014YY051）
山东省自然科学基金资助项目(NoZR2015PH002) （NoZR2015PH002）
山东省医药卫生科技发展计划(No2014WS0479) （No2014WS0479）
山东省高等学校科技计划(NoJ15LM51) （NoJ15LM51）
